- Home
- RBOT vs APLT Comparison
RBOT vs APLT Comparison
Compare RBOT & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- APLT
- Stock Information
- Founded
- RBOT 2014
- APLT 2016
- Country
- RBOT United States
- APLT United States
- Employees
- RBOT N/A
- APLT N/A
- Industry
- RBOT Medical Specialities
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- APLT Health Care
- Exchange
- RBOT Nasdaq
- APLT Nasdaq
- Market Cap
- RBOT 46.7M
- APLT 44.0M
- IPO Year
- RBOT N/A
- APLT 2019
- Fundamental
- Price
- RBOT $8.09
- APLT $0.41
- Analyst Decision
- RBOT Hold
- APLT Buy
- Analyst Count
- RBOT 2
- APLT 7
- Target Price
- RBOT $9.25
- APLT $6.10
- AVG Volume (30 Days)
- RBOT 11.3K
- APLT 2.6M
- Earning Date
- RBOT 08-11-2025
- APLT 08-06-2025
- Dividend Yield
- RBOT N/A
- APLT N/A
- EPS Growth
- RBOT N/A
- APLT N/A
- EPS
- RBOT N/A
- APLT N/A
- Revenue
- RBOT N/A
- APLT $265,000.00
- Revenue This Year
- RBOT N/A
- APLT $1,768.13
- Revenue Next Year
- RBOT N/A
- APLT $292.85
- P/E Ratio
- RBOT N/A
- APLT N/A
- Revenue Growth
- RBOT N/A
- APLT N/A
- 52 Week Low
- RBOT $4.27
- APLT $0.30
- 52 Week High
- RBOT $19.00
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- RBOT 53.93
- APLT 58.87
- Support Level
- RBOT $7.21
- APLT $0.32
- Resistance Level
- RBOT $8.02
- APLT $0.36
- Average True Range (ATR)
- RBOT 0.43
- APLT 0.04
- MACD
- RBOT 0.01
- APLT 0.01
- Stochastic Oscillator
- RBOT 69.92
- APLT 94.92
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.